SOCS-3表达水平对CHC患者Peg-IFN/RBV疗效预测价值的探讨

Investigation of the therapeutic predictive value of SOCS-3 in combination therapy with Peg-IFN/ RBV in patients with chronic hepatitis C

目的 通过研究CHC患者基线外周血的SOCS-3表达水平,探讨其对聚乙二醇干扰素联合利巴韦林抗病毒治疗快速应答的预测价值.方法 68例接受PEG-IFN联合利巴韦林治疗的CHC患者,于基线时采集患者全血,提取PBMC总RNA,逆转录合成cDNA,用实时荧光定量PCR检测SOCS-3 mRNA的相对含量.采集临床资料,检测病毒载量、生化指标、HCV基因型.结果 治疗4周时,38例患者获得快速病毒学应答（RVR）,与无快速应答（NRVR）的30例患者相比,治疗前外周血的SOCS-3 mRNA的相对表达水平分别为0.0112±0.0071和0.0220±0.0205,差异有统计学意义（u=-2.322,P=0.020）;RVR与NRVR患者的年龄、性别比例、HCV基因型、HCV RNA、ALT、AST、TB、ALB、GLB、外周血WBC及PLT比较,无统计差异.SOCS-3低表达组（＜0.0072）、中表达组（≥0.0072,＜0.0223）及高表达组（≥0.0223）,RVR患者分别为12例（80.00％）、23例（56.09％）和3例（25.00％）,有统计差异（x2 =8.182,P=0.016）.结论 基线SOCS-3表达水平,对慢性丙型肝炎Peg-IFN/RBV治疗RVR有预测价值。

Objective To investigate the expression of SOCS-3 in the peripheral blood and discuss its predictive value of RVR in combination therapy with pegylated interferon alpha and ribavirin in patients with chronic hepatitis C.Methods 68 patients with chronic hepatitis C received combination therapy with pegylated interferon alpha and ribavirin,at baseline,total RNA was eluted from peripheral blood mononuclear cells（PBMCs） and synthesis of cDNA by reverse transcription were carried out,and then realtime RT-PCR was used to detect SOCS3 mRNA relative contents.Clinical data,HCV RNA virus load,biochemical parameters,HCV genotype were collected.Results After 4 weeks treatment,38 patients obtained RVR,and compared with 30 cases of NRVR,SOCS3 mRNA relative contents at baseline were 0.0112 ± 0.0071 和 0.0220 ± 0.0205 （u =-2.322,P =0.020）;there was no significant difference between RVR and NRVR in patient＇s age,sex ratio,HCV genotype,HCV RNA virus load,ALT,AST,TB,ALB,GLB,peripheral blood WBC and PLT.There were 12 cases（80.00%）,23 cases（56.09%）and 3 cases（25.00%） in SOCS-3 low expression group （〈 0.0072）,medium expression group （≥ 0.0072,〈 0.0223） and high expression group （≥ 0.0223） obtained RVR respectively,the difference was significant （x2 =8.182,P =0.016）.Conclusion SOCS-3 has predictive value of RVR in combination therapy with Peg-IFN/RBV in patients with chronic hepatitis C.